Top entities: Neuronetics, Greenbrook TMS, Geoffrey Grammer, United States — Food and Drug Administration, Cory Anderson.

What category does this event fall under?

Business — classified as facility opening.

What is the sentiment of coverage?

Aggregate sentiment score: 10 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Jul 28, 2026. Coverage continues to evolve.

Business facility opening

Neuronetics opens Rockville Center of Excellence

Q: When did this event occur?

First reported Jul 28, 2026; last updated Jul 28, 2026.

Q: What is the market impact?

General. The opening expands Neuronetics' direct patient care footprint and positions the company for future growth in interventional psychiatry.

Analysis based on 6 articles · First reported Jul 28, 2026 · Last updated Jul 28, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The opening expands Neuronetics' direct patient care footprint and positions the company for future growth in interventional psychiatry. The investment signals confidence in the mental health treatment market, potentially boosting investor sentiment.

Healthcare Mental Health

Event Summary

Neuronetics, Inc. announced the grand opening of Greenbrook TMS' National Center of Excellence in United States — Rockville, Maryland. The nearly 7,000-square-foot facility is the largest Greenbrook center to date and serves as a flagship innovation center and blueprint for future care delivery. Overseen by Chief Medical Officer Geoffrey Grammer, the center offers NeuroStar TMS therapy and SPRAVATO (esketamine) treatments, and is REMS-certified. It will also serve as a pilot site for emerging therapies, including potential psychedelic-class treatments pending FDA approval.

Key Actions

70 Neuronetics opened

Entities Involved

stock

Neuronetics

Neuronetics announced and operates the new Center of Excellence, reinforcing its leadership in interventional mental health and expanding its clinic network.

Importance 100.0 Sentiment 15.0

stock

Greenbrook TMS

Greenbrook, a subsidiary of Neuronetics, operates the new flagship center, enhancing its capacity to deliver advanced treatments and serve as a national blueprint.

Importance 80.0 Sentiment 15.0

per

Geoffrey Grammer

Dr. Grammer provides clinical leadership as Chief Medical Officer and maintains clinical hours at the center, contributing to its innovation and patient care.

Importance 50.0 Sentiment 10.0

govactor

United States — Food and Drug Administration

The FDA's potential approval of emerging psychedelic-class therapies could enable Greenbrook to incorporate them into its model of care.

Importance 40.0 Sentiment 0.0

per

Cory Anderson

Cory Anderson, Executive Vice President and General Manager of Greenbrook, highlighted the center's role as a blueprint for future interventional psychiatry.

Importance 30.0 Sentiment 5.0

loc

United States — Rockville, Maryland

Rockville is the location of the new Center of Excellence, benefiting from expanded access to advanced mental health treatments.

Importance 20.0 Sentiment 5.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard